Oncology · RAS MutationsTrial Updateclinicalmid-term

Adlai Nortye initiates trial for AN4035 in RAS-mutated advanced cancers

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/16/2026, 6:31:12 PM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the AN4035 trial by Adlai Nortye represents a significant step in addressing the unmet need for effective therapies in RAS-mutated advanced cancers. The outcomes of this trial could reshape competitive dynamics in oncology and influence strategic partnerships. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 25 ranked evidence items (9 high-relevance).

Strategic Assessment

Success in this trial could position AN4035 as a key player in the treatment of RAS-mutated cancers, influencing portfolio strategies and partnerships. The strongest clinical anchor is A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression (ClinicalTrials.gov), entity match (adlai nortye biopharma); patient population match (advanced). In Oncology · RAS Mutations, 4 regulatory and 5 competitive items passed relevance filtering for Adlai Nortye Biopharma.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer); patient population match (advanced). Secondary pressure from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC).

Regulatory Outlook

Regulatory risk is concentrated around MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer (MHRA). Patient population match (advanced). Relevant agencies in corpus: MHRA, FDA. Successful trial results could facilitate expedited regulatory pathways, enhancing the likelihood of approval for AN4035 in a critical therapeutic area.

Key Risks

Elevated medium regulatory exposure for Adlai Nortye Biopharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If AN4035 demonstrates efficacy, it could capture market share in a competitive landscape, potentially leading to significant revenue opportunities for Adlai Nortye.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
Lead sponsor: Hoffmann-La Roche. The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and efficacy, particularly the recommended dose and any observed anti-cancer activity.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAhigh relevance
Patient population match (advanced)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Frutas Hortalizas del Sur S.A. Initiates Recall of Frozen GreenWise Organic IQF Blueberries Due to Potential E.
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
ClinicalTrials.govhigh relevance
Entity match (adlai nortye biopharma); Patient population match (advanced)
FDA document
View source
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Meta
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (advanced)
FDA document
View source
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
ClinicalTrials.govmedium relevance
Patient population match (advanced)
FDA document
View source
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
ClinicalTrials.govmedium relevance
Patient population match (advanced)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer); Patient population match (advanced)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck); Patient population match (advanced)
FDA document
View source
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Tislelizumab and Disitamab-Vedotin Show Promise in Neoadjuvant Therapy for HER2-positive UTUC
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effect of different liposomal bupivacaine concentrations in ultrasound-guided superior trunk block on postoperative analgesia and mobility: a randomized double-blind controlled trial protocol for shou
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
CD69 blockade restores the bone marrow niche and delays leukemogenesis in a mouse model of Nras (G12D)-driven chronic myelomonocytic leukemia.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Contrasting dietary patterns remodel gut microbial function and generate multi-omic signatures associated with cardiometabolic markers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Clinical research progress and challenges of vaccine for human papillomavirus-associated cancers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Survival Nomogram for Stage IV (M1a-c) Melanoma: A Population-Based Study Highlighting the Prognostic Correlates of Surgery in Pre-Immunotherapy and Early Immunotherapy Eras.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Adlai Nortye Biopharma
AN4035
cetuximab

Commercial impact

medium

If AN4035 demonstrates efficacy, it could capture market share in a competitive landscape, potentially leading to significant revenue opportunities for Adlai Nortye.

Regulatory impact

medium

Successful trial results could facilitate expedited regulatory pathways, enhancing the likelihood of approval for AN4035 in a critical therapeutic area.

What to watch

Monitor trial results for safety and efficacy, particularly the recommended dose and any observed anti-cancer activity.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.